tirzepatide surpass Once Weekly in Children and Adolescents with Type 2 Diabetes ( SURPASS-Peds). The New England Journal of Medicine. 2024;391:XXX–XXX. doi:10.1056/NEJMoa2400938 SURPASS-CVOT Published: Large Trial Confirms

* Nota : A dose inicial mais baixa (3,0 mg dirios) destina-se a reduzir os sintomas adversos gastrointestinais, porm no fornece um controle glicmico efetivo

Apr 2, 2026 Americans pay more for GLP-1 medications than almost anyone else on earth

This review provides a foundation for future research on emerging molecular targets and experimental therapeutics that can ultimately improve long-term quality of life in patients undergoing paclitaxel-based chemotherapy

Jyonouchi, H., et al., Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention